Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01453296 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01453296 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 28 participants.
The verdict
NCT01453296, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.
Interventions
- DRUG Placebo
- DRUG GW642444
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01453296
The ClinicalTrials.gov registry entry for NCT01453296 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01453296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01453296 about?
NCT01453296 is a clinical study titled "Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects". This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.
What is the current status of trial NCT01453296?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2010-08. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01453296?
The interventions under investigation include: Placebo (DRUG), GW642444 (DRUG).
Who is sponsoring clinical trial NCT01453296?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.